Positive Press Coverage Somewhat Unlikely to Affect BG Medicine (BGMD) Share Price
News coverage about BG Medicine (NASDAQ:BGMD) has been trending positive on Monday, according to Accern Sentiment Analysis. Accern rates the sentiment of news coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. BG Medicine earned a news sentiment score of 0.26 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 44.0699084991908 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
BG Medicine (NASDAQ:BGMD) traded up 0.000% during midday trading on Monday, reaching $0.045. The firm’s market capitalization is $509355.03. BG Medicine has a 12-month low of $0.03 and a 12-month high of $0.20. The stock has a 50 day moving average price of $0.05 and a 200-day moving average price of $0.07.
About BG Medicine
BG Medicine, Inc (BG Medicine) is a commercial-stage diagnostics company. The Company is engaged in commercializing diagnostic products that may be used to help guide the care and management of patients suffering from heart failure and related disorders. The Company’s BGM Galectin-3 Test is an in vitro diagnostic device that employs a manual micro-titer platform to measure galectin-3 levels in blood plasma or serum for use as an aid in assessing the prognosis of chronic heart failure in conjunction with clinical evaluation.
Receive News & Ratings for BG Medicine Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BG Medicine Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.